Eli Lilly and Company × Alzheimers
Eli Lilly and Company alzheimers: 3 indexed trials, 1 recruiting studies across 1 countries in the current NeuroRisk corpus.
Request comparative brief →Indexed trials3
Recruiting1
Countries1
Indexed studies
NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
United StatesPHASE3
United StatesPHASE3
NCT01837641A Study of LY3002813 in Participants With Alzheimer's Disease
United StatesPHASE1
United StatesPHASE1
NCT03367403A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
United StatesPHASE2
United StatesPHASE2
Enterprise comparison
Compare sponsor momentum, recruiting activity, geography and connected evidence with the broader NeuroRisk intelligence layer.
Request enterprise access →